10月2日 - ** 药物开发商Bolt Biotherapeutics BOLT.O股价盘前下跌13.6%至4.89美元
** 该公司周三表示，它正在修改癌症药物BDC-4182早期试验的设计 (link)，现在预计将于2026年第三季度发布初步数据。
** 公司表示，更新后的方案将包括阶梯给药，这是一种用于类似疗法的方法，有助于减少副作用。
** 公司还将裁员约 50%，以将现金流延长至 2027 年
** 截至上一交易日收盘，股价累计下跌 47
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.